Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-OXINDOLE COMPOUNDS
    Publication number: 20200123136
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: July 29, 2019
    Publication date: April 23, 2020
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS
    Publication number: 20200121688
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Application
    Filed: September 23, 2019
    Publication date: April 23, 2020
    Inventors: Junfa FAN, Jaroslaw Kalisiak, Rebecca M. LUI, Venkat Reddy MALI, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES
    Publication number: 20200113898
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 16, 2020
    Inventors: Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN
  • CXCR7 ANTAGONISTS
    Publication number: 20200095251
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 9, 2019
    Publication date: March 26, 2020
    Inventors: Junfa FAN, Antoni KRASINSKI, Christopher W. LANGE, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
  • Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides
    Patent number: 10596163
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: March 24, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Junfa Fan, Pingchen Fan, Antoni Krasinski, Lianfa Li, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20200069673
    Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 5, 2020
    Inventors: Shijie LI, Venkat Reddy MALI, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
    Patent number: 10568870
    Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 25, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Israel Charo, Heiyoun Jung, Thomas J. Schall, Penglie Zhang
  • Indane-amines as PD-L1 antagonists
    Patent number: 10568874
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 25, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • MACROCYCLIC IMMUNOMODULATORS
    Publication number: 20200055869
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 8, 2019
    Publication date: February 20, 2020
    Inventors: Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
  • 6-5 fused rings as C5a inhibitors
    Patent number: 10562896
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 18, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20200039969
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Application
    Filed: May 16, 2019
    Publication date: February 6, 2020
    Inventors: Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-?4?7 integrin blocking antibodies
    Patent number: 10532051
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 14, 2020
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
  • Processes and intermediates in the preparation of C5aR antagonists
    Patent number: 10532982
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 14, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Soluble C5aR antagonists
    Patent number: 10487098
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 26, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Substituted tetrahydropyrans as CCR2 modulators
    Patent number: 10464934
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: November 5, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
    Publication number: 20190300526
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Inventors: Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG
  • 2-oxindole compounds
    Patent number: 10421748
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: September 24, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • INDANE-AMINES AS PD-L1 ANTAGONISTS
    Publication number: 20190282555
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: February 21, 2019
    Publication date: September 19, 2019
    Inventors: Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
    Publication number: 20190276402
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 12, 2019
    Inventors: Pingchen FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Rebecca M. LUI, Jay POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • SOLUBLE C5aR ANTAGONISTS
    Publication number: 20190270761
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 5, 2019
    Inventors: Pingchen FAN, Antoni KRASINSKI, Venkat Reddy MALI, Shichang MIAO, Sreenivas PUNNA, Yang SONG, Valentino J. STELLA, Yibin ZENG, Penglie ZHANG